IRMD - NASDAQ
IRadimed Corporation
$94.48
+5.1%IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
At a Glance
Live SnapshotIRadimed Corporation Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Outstanding operational efficiency. The company generates substantial profit from core operations.
Net Profit Margin
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Effective Tax Rate
Moderate tax rate typical for most corporations. Represents standard tax burden on profits.
Profitability Insight
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
IRadimed Corporation Income Statement
IRMD • NASDAQ
| IRadimed Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||
83.8M | 73.2M | 65.6M | 53.3M | 41.8M | 31.7M | 38.5M | 30.4M | 23.1M | 32.5M | 31.6M | 15.7M | 11.3M | 7.7M | |
GROSS PROFIT | ||||||||||||||
(19.5M) | (16.9M) | (15.4M) | (12M) | (9.8M) | (8.1M) | (8.8M) | (7.2M) | (5.6M) | (6.2M) | (5.8M) | (3.4M) | (2.9M) | (2.1M) | |
64.3M | 56.3M | 50.2M | 41.3M | 32M | 23.6M | 29.7M | 23.2M | 17.5M | 26.3M | 25.8M | 12.2M | 8.5M | 5.6M | |
OPERATING INCOME | ||||||||||||||
(38.2M) | (34.4M) | (30.1M) | (25.7M) | (22.2M) | (24.3M) | (21.1M) | (17.2M) | (16.2M) | (15.4M) | (14.2M) | (9.2M) | (5.7M) | (4.1M) | |
(35.2M) | (31.6M) | (27.3M) | (23.4M) | (20.3M) | (22.4M) | (19.6M) | (15.7M) | (14.5M) | (14.1M) | (12.5M) | (8.1M) | (4.7M) | (3.5M) | |
(3M) | (2.8M) | (2.9M) | (2.3M) | (1.9M) | (1.9M) | (1.4M) | (1.5M) | (1.7M) | (1.3M) | (1.8M) | (1.1M) | (1M) | (654.1K) | |
26.1M | 22M | 20M | 15.6M | 9.8M | -756.1K | 8.6M | 6M | 1.3M | 10.9M | 11.5M | 3.1M | 2.8M | 1.4M | |
PRE-TAX INCOME | ||||||||||||||
0.0 | 2.2M | 1.9M | 581.9K | 34.8K | 132.2K | 388.8K | 238.1K | 122.6K | 126.4K | 148.9K | 5.7K | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (111.4K) | (32.7K) | (121.4K) | -48.5K | -3.5K | (7.4K) | |
2.2M | 2.3M | 1.7M | 553.1K | 18.6K | 139.2K | 395.9K | 193.5K | 111.4K | 32.7K | 121.4K | -48.5K | -3.5K | 7.4K | |
28.4M | 24.3M | 21.7M | 16.2M | 9.8M | -616.9K | 9M | 6.2M | 1.4M | 11M | 11.6M | 3M | 2.8M | 1.4M | |
NET INCOME | ||||||||||||||
(5.9M) | (5M) | (4.5M) | (3.4M) | (510.8K) | -2M | -587.6K | -106.1K | (896.6K) | (3.7M) | (4.1M) | (967K) | (846.9K) | (466K) | |
22.5M | 19.2M | 17.2M | 12.8M | 9.3M | 1.4M | 9.6M | 6.3M | 499.8K | 7.2M | 7.5M | 2.1M | 1.9M | 966.1K |
SEC Filings
IRMD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 01, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 01, 2026 | May 01, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 06, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 10, 2026 | February 10, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 05, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 03, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 03, 2025 | November 03, 2025 | 2025 | |
10-K/A 10-K/A 2024 FY (Amended) FY | September 03, 2025 | December 31, 2024 | 2024 | |
8-K 8-K 2025 N/A | September 02, 2025 | August 27, 2025 | 2025 |
Related Guides
Continue your IRMD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.